Urovant Sciences Ltd.
UROV
UROV was delisted on the 26th of March, 2021.
34 hedge funds and large institutions have $86.3M invested in Urovant Sciences Ltd. in 2018 Q3 according to their latest regulatory filings, with 34 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
23.53% more ownership
Funds ownership: 0% → 23.53% (+24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.2M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$7.03M |
| 4 |
SCM
Sio Capital Management
New York
|
+$6.99M |
| 5 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$6.21M |
Top Sellers
UROV Hedge Fund Activity: Q3 2018 in Review
34 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Urovant Sciences Ltd. (UROV) for Q3 2018, worth a combined $86.3M.
Buyers outnumbered sellers: 34 funds opened new UROV positions and 0 closed out — a net gain of 34 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $14.4M.
- 34 institutional investors held Urovant Sciences Ltd. (UROV) as of Q3 2018, up from 0 in Q2 2018.
- Funds reported $86.3M of Urovant Sciences Ltd. stock for Q3 2018.
- 34 funds opened new Urovant Sciences Ltd. positions in Q3 2018 and 0 closed out, a net change of +34 holders.
- The largest Urovant Sciences Ltd. buyer in Q3 2018 was Adage Capital Partners, an estimated $14.4M added.
Based on aggregated 13F filings for Q3 2018.